Rogel Cancer Center: University of Michigan
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
Phase 2
Terminated
- Conditions
- LeukemiaLymphoma, Low-GradeLymphoma, Non-Hodgkin'sMultiple MyelomaMyelodysplastic Syndromes
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-04-23
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00143884
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Phase 2
Completed
- Conditions
- Multiple MyelomaLymphocytic Leukemia, ChronicLymphoma, Low-Grade
- Interventions
- Procedure: Reduced intensity conditioningProcedure: Rapid immunosuppressive taperProcedure: Prophylactic donor leukocyte infusions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00143845
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
Phase 2
Terminated
- Conditions
- Lymphoma, Non-Hodgkin's
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00141700
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
Phase 2
Completed
- Conditions
- Lung Injury, AcuteRespiratory Distress Syndrome, AdultBronchiolitis Obliterans
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00141726
- Locations
- 🇺🇸
The University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
Phase 2
Completed
- Conditions
- Wilms TumorFibrosarcomaCarcinoma, Round CellNasopharyngeal CancerBrain Tumor, Recurrent
- Interventions
- Procedure: Myeloablative ChemotherapyProcedure: Stem Cell Rescue
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00141765
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT00141739
- Locations
- 🇺🇸
Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸The University of Michigan, Ann Arbor, Michigan, United States
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00141713
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
Phase 2
Completed
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT00136175
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00135200
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
Not Applicable
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00135187
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath